216 related articles for article (PubMed ID: 22683647)
1. Exploring the effects of high shear blending on lactose and drug using fluidised bed elutriation.
Willetts JP; Robbins PT; Roche TC; Bowley M; Bridson RH
Int J Pharm; 2012 Sep; 434(1-2):272-9. PubMed ID: 22683647
[TBL] [Abstract][Full Text] [Related]
2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
4. The effects of high shear blending on alpha-lactose monohydrate.
Bridson RH; Robbins PT; Chen Y; Westerman D; Gillham CR; Roche TC; Seville JP
Int J Pharm; 2007 Jul; 339(1-2):84-90. PubMed ID: 17398047
[TBL] [Abstract][Full Text] [Related]
5. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
6. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
7. Entrainment of lactose inhalation powders: a study using laser diffraction.
Watling CP; Elliott JA; Cameron RE
Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
[TBL] [Abstract][Full Text] [Related]
8. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
9. Blending of agglomerates into powders 1: Quantification of abrasion rate.
Willemsz TA; Oostra W; Hooijmaijers R; de Vegt O; Morad N; Vromans H; Frijlink HW; Van der Voort Maarschalk K
Int J Pharm; 2010 Mar; 387(1-2):87-92. PubMed ID: 20015470
[TBL] [Abstract][Full Text] [Related]
10. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
11. Experimental observations of dry powder inhaler dose fluidisation.
Tuley R; Shrimpton J; Jones MD; Price R; Palmer M; Prime D
Int J Pharm; 2008 Jun; 358(1-2):238-47. PubMed ID: 18457930
[TBL] [Abstract][Full Text] [Related]
12. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
13. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
14. Impact of high shear blending on distribution of magnesium stearate on lactose for dry powder inhaled formulations.
Welle A; Mehta M; Marek K; Peters H; van der Wel P; Imole O
Int J Pharm; 2023 Nov; 647():123503. PubMed ID: 37827391
[TBL] [Abstract][Full Text] [Related]
15. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
16. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
17. Functionality testing of inhalation grade lactose.
Steckel H; Markefka P; TeWierik H; Kammelar R
Eur J Pharm Biopharm; 2004 May; 57(3):495-505. PubMed ID: 15093599
[TBL] [Abstract][Full Text] [Related]
18. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
Thalberg K; Åslund S; Skogevall M; Andersson P
Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
[TBL] [Abstract][Full Text] [Related]
19. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
Cordts E; Steckel H
Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
[TBL] [Abstract][Full Text] [Related]
20. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
